Target intelligence / Profile preview

Mitochondrial ornithine transporter 1 (SLC25A15)

Target
SLC25A15
Molecular classification
Transporter, Solute carrier family (SLC25), Mitochondrial carrier protein
01

Overview

Mitochondrial ornithine transporter 1 (SLC25A15) is a mitochondrial inner membrane transporter that exchanges cytosolic ornithine with mitochondrial citrulline and protons, serving a critical role in the urea cycle by enabling the detoxification of ammonia in hepatocytes. Loss-of-function mutations in SLC25A15 cause hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome, a rare autosomal recessive disorder characterized by elevated blood ornithine and ammonia, with neurological dysfunction, protein intolerance, and risk of life-threatening hyperammonemic crises. SLC25A15 is a member of the solute carrier family 25, a large group of mitochondrial transporters, and is essential for linking the cytosolic steps of the urea cycle with intramitochondrial reactions. Treatment primarily involves ammonia-scavenging drugs, dietary protein restriction, and arginine supplementation, but direct pharmacological inhibitors or activators of SLC25A15 are not in clinical use. Deficiency of this transporter leads to accumulation of toxic ammonia, particularly affecting the central nervous system, and can result in severe clinical outcomes if untreated.

Other names
ORNT1ORC1Ornithine transporter 1Ornithine carrier 1Solute carrier family 25 member 15Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome proteinD13S327HHH proteinSolute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15
02

Mechanism of action

Drugs do not directly inhibit SLC25A15 but act by scavenging ammonia or supporting the deficient pathway

03

Biological functions

Urea cycleAmmonium detoxificationMitochondrial ornithine/citrulline exchangeAmino acid metabolism (arginine biosynthesis)
04

Disease associations

Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndromeOther urea cycle disorders
05

Safety considerations

Hyperammonemia risk (neurological toxicity, hepatic injury, risk of encephalopathy)Therapy can be challenging, requiring lifelong protein restriction and supplementationDelays in diagnosis/treatment can cause irreversible neurological damage
06

Interacting drugs

Sodium benzoate (used in management of urea cycle disorders, not a direct molecular inhibitor but modulates cycle biochemistry)

2 more in the full profile.

07

Biomarkers

Plasma ammonia (hyperammonemia)Plasma ornithine (hyperornithinemia)Homocitrulline in urine (homocitrullinuria)

Beyond the preview

Go deeper on Mitochondrial ornithine transporter 1 (SLC25A15).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrial ornithine transporter 1 (SLC25A15).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call